1620s, from Late Latin oralis , from Latin os (genitive oris ) "mouth, opening, face, entrance," from PIE *os-/*ous- "mouth" (cf. Sanskrit asan "mouth," asyam "mouth, opening," Avestan ah- , Hittite aish , Middle Irish a "mouth," Old Norse oss "mouth of a river," Old English or "beginning, origin, front"). Psychological meaning "of the mouth as the focus of infantile sexual energy" (. oral fixation ) is from 1910. The sexual sense is first recorded 1948, in Kinsey. As a noun, "oral examination," attested from 1876. Related: Orally (); orality .
The influence of pyralgin, acenol, hydroxizinum and scopolan administered orally on the amount of the saliva excreted and pocket fluid as well as one the patients' feeling during stomatological treatment has been examined by the dual blind test method. The examinations haven't proved any significant influence of these drugs on the excretion of the saliva and pocket fluid of a statistical importance; these drugs, however, have reduced the painfulness of the operations depending on hard dental tissues processing. Among the drugs applied Pyralgin has proved to be the most useful drug for patients premedication before stomatological treatment.
Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Individuals who have already experienced NAION are at increased risk of NAION recurrence. Therefore, PDE5 inhibitors, including Staxyn, should be used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with “crowded” optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including STAXYN, for this uncommon condition.